Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444180 | 1.00 | KDM4E (0.39) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3116309 | 0.89 | MEN1 (0.40) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3119390 | 0.89 | MEN1 (0.40) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3116317 | 0.89 | MEN1 (0.40) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3745483 | 0.88 | NPC1 (0.42) | KDM4ENPC1RAB9AMDM2ALDH1A1 | |
| SCHEMBL2446754 | 0.86 | ALDH1A1 (0.43) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3120504 | 0.84 | MBOAT4 (0.46) | KDM4ECYP3A4LMNAPOLB | |
| SCHEMBL3120493 | 0.84 | MBOAT4 (0.46) | KDM4ECYP3A4LMNAPOLB | |
| SCHEMBL3753204 | 0.83 | GPR119 (0.41) | KDM4EKMT2AALDH1A1CYP3A4LMNA | |
| SCHEMBL3753200 | 0.83 | GPR119 (0.41) | KDM4EKMT2AALDH1A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017780-B1 | Therapeutic compounds and uses thereof | MYREXIS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | KDM4E 3910/4885MEN1 688/4885KMT2A 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.